the market?
Rigel Pharmaceuticals, Inc.
NASDAQ: RIGL
4.71
0.07
(1.51%)
| Today's Open | $4.65 |
|---|---|
| Previous Close | $4.64 |
| Daily Range | $4.60 - $4.73 |
| 52-Week Range | $4.41 - $11.44 |
| Market Cap | $410.4M |
| P/E Ratio | -3.60 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 360,150 |
| Average Daily Volume | 900,124 |
| Current FY EPS | -$0.89 |
How do you think RIGL
will perform against the market?
Top RIGL Bull/Bear Pitches
zzlangerhans (< 20)
Submitted
November 17, 2010
Rigel is a company I always keep my eye on when the share price is low, because of the explosion in their share price that occurred in late 2007 with encouraging phase II data for their RA drug R788, … More
1337172979 (< 20)
Submitted
November 29, 2010
Rigel's lead compound is fosfamatinib for rheumatoid arthritis. In September 2010, licensee AstraZeneca initiated the OSKIRA phase III RA program which would consist of three pivotal studies to be fol … More
News & Commentary
3 Biggest Biotech Crashes in April
When biotechs fall, they fall hard. These three fell the hardest in April.Why Rigel Is Poised to Bounce Back
Market-trouncing returns could be written in this 4-star stock.3 Horrendous Health-Care Stocks This Week
The week of April Fools' Day was no joking matter for these 3 stocks.Growing Aches and Pains Sink Rigel Pharmaceuticals
Mixed late-stage trial data backs Rigel's rheumatoid arthritis drug up against the wall.JPMorgan Healthcare Conference Rewind: Rigel Pharmaceuticals
Does the clinical-stage company have a strong pipeline to back a faltering lead?3 Health Care Companies I'm Watching Today
Three companies worth watching at the J.P. Morgan Healthcare Conference.Sector
Healthcare
Industry
Drugs
Rigel Pharmaceuticals, Inc. (RIGL) Description
The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Website: http://www.rigel.com/
More details for Rigel Pharmaceuticals Jobs
Rigel Pharmaceuticals reviews from employees
